

Grindex



Make health your habit!

Make health your habit!



Grindeks is the leading pharmaceutical manufacturer in the Baltic States, headquartered in Riga, Latvia, with a history dating back to 1946. Today, our products are available in more than 100 countries worldwide.

Our portfolio includes original medicines, generic medicines and active pharmaceutical ingredients manufactured in accordance with high international standards of quality and safety.

We focus on developing medicines in the fields of cardiology, neurology, oncology, endocrinology, and dermatology.





Main therapeutic groups



Oncology



Central Nervous
System



Cardiovascular
System



Dermatology



Diabetes



Corporate social responsibility priorities

We put health and safety first for both patients and employees, while protecting the environment through more sustainable practices and digitalisation, and upholding high ethical standards across every aspect of our pharmaceutical business.



Grindeks Quality certification

EU
GMP

EU
GDP

ISO
9001

ISO
45001

Saudi
FDA

ISO
14001

ISO
50001

PMDA

US
FDA

Grindeks product portfolio



Active substance	Strength	Pharmaceutical form	Pack size	Pharmacotherapeutic group	ATC code
Antineoplastic and Immunomodulating Agents					
Lenalidomide	2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg	Hard capsules	N7, N21	Immunosuppressant	L04AX04
Pomalidomide	1 mg, 2 mg, 3 mg, 4 mg	Hard capsules	N14, N21	Immunomodulating agent	L04AX06
Cardiovascular System					
Apixaban	2.5 mg, 5 mg	Film-coated tablets	N10, N20, N28, N30, N56, N60, N100, N168, N200	Antithrombotic agent, direct factor Xa inhibitor	B01AF02
Lisinopril	5 mg, 10 mg, 20 mg	Tablets	N14, N28, N30, N56, N60, N84, N98	Angiotensin converting enzyme inhibitor	C09AA03
Meldonium dihydrate	100 mg/ml	Solution for injection, 5 ml, 10 ml	N5, N10, N20	Other cardiac preparation	C01EB22
Meldonium dihydrate	500 mg	Hard capsules	N20, N60, N90	Other cardiac preparation	C01EB22
Rilmenidine	1 mg	Tablets	N30, N60, N90	Antihypertensive	C02AC06
Rivaroxaban	10 mg, 15 mg, 20 mg	Film-coated tablets	N10, N14, N28, N30, N42, N98, N100	Antithrombotic agent, direct factor Xa inhibitor	B01AF01
Central Nervous System					
Alprazolam	0.25 mg, 0.5 mg, 1 mg	Tablets	N10, N20, N30, N50, N60, N100	Benzodiazepine derivative	N05BA12
Bupivacaine hydrochloride	5 mg/ml	Injection, 10 ml	N5, N10	Local anaesthetic	N01BB01
Bupivacaine hydrochloride Spinal	5 mg/ml	Injection, 4 ml	N5	Local anaesthetic	N01BB01
Bupivacaine hydrochloride Heavy	5 mg/ml	Injection, 4 ml	N5	Local anaesthetic	N01BB01
Ipidacrine hydrochloride	20 mg	Tablets	N50, N100	Parasympathomimetic, anticholinesterase	N07AA
Ipidacrine hydrochloride	5 mg/ml, 15 mg/ml	Solution for injection, 1 ml	N10	Parasympathomimetic, anticholinesterase	N07AA
Lacosamide	50 mg, 100 mg, 150 mg, 200 mg	Film-coated tablets	N14, N56, N168	Antiepileptics	N03AX18
Lidocaine hydrochloride	10 mg/ml, 20 mg/ml	Solution for injection 2 ml, 5 ml, 10 ml (ampoules), 20 ml, 50 ml (vials)	N2, N5, N10, N20, N50 (ampoules) N10 (vials)	Local anaesthetic, amide	N01BB02

Active substance	Strength	Pharmaceutical form	Pack size	Pharmacotherapeutic group	ATC code
Memantine Hydrochloride	10 mg, 20 mg	Film-coated tablets	N10, N14, N20, N28, N30, N40, N50, N56, N60, N90, N98, N100, N112	Psychoanaleptic	N06DX01
Mirtazapine	15 mg, 30 mg, 45 mg	Orodispersible tablets	N28, N30, N50, N56, N60, N100	Other Antidepressant	N06AX11
Pregabalin	25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg	Hard capsules	N14, N21, N28, N56, N60, N84, N90, N98, N100, N200	Other analgesics and antipyretics	N02BF02
Risperidone	0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 6 mg	Film-coated tablets	N20, N30, N60, N100	Other antipsychotic	N05AX08
Sulpiride	50 mg, 100 mg, 200 mg	Tablets	N30, N100	Psycholeptic	N05AL01
Zopiclone	3.75 mg, 5 mg, 7.5 mg	Film-coated tablets	N10, N20, N30, N60, N100	Hypnotics and sedatives, benzodiazepine related drug	N05CF01
Dermatology					
Dexpanthenol	50 mg/g	Ointment	30 g, 50 g	Treatment of wounds and ulcers	D03AX03
Dexpanthenol	50 mg/g	Cream	30 g, 50 g	Treatment of wounds and ulcers	D03AX03
Dimetindene maleate	1 mg/g	Gel	30 g, 50 g	Antihistamine for the topical use	D04AA13
Ketoconazole	20 mg/g	Shampoo	60 g, 100 g	Antifungal for dermatological use	D01AC08
Endocrine System					
Oxytocin	5 IU/ml, 10 IU/ml	Solution for injection, 1 ml	N5, N10, N100	Pituitary and hypothalamic hormone and analogue	H01BB02
Sitagliptin	25 mg, 50 mg, 100 mg	Film-coated tablets	N14, N28, N56, N98	Drug used in diabetes	A10BH01
Sitagliptin/ Metformin hydrochloride	50 mg/850 mg, 50 mg/1000 mg	Film-coated tablets	N28, N56, N98, N196	Drug used in diabetes	A10BD07
Others					
Ursodeoxycholic acid	250 mg	Hard capsules	N50, N60, N100	Bile and liver therapy	A05AA02
Loperamide hydrochloride	2 mg	Hard capsules	N6, N8, N10, N12, N16, N18, N20	Antipropulsive	A07DA03

Under Development					
Betamethasone valerate	1 mg/g	Ointment	15 g, 30 g, 50 g, 100 g	Topical corticosteroid	D07AC01
Betamethasone valerate	1 mg/g	Cream	15 g, 30 g, 50 g, 100 g	Topical corticosteroid	D07AC01
Clozapine	25 mg, 100 mg	Tablets	N14, N28, N30, N40, N50, N60, N84, N100	Psycholeptics	N05AH02
Donepezil	5 mg, 10 mg	Film coated tablets	N28, N30, N56, N98, N100, N250	Anti-dementia drugs, Anticholinesterase;	N06DA02
Hydrocortisone butyrate	1 mg/g	Cream	15 g, 30 g, 50 g, 100 g	Topical corticosteroid	D07AB02
Imatinib	100 mg, 400 mg	Hard capsules	N 30, N60, N120	Antineoplastic agent	L01EA01
Lamotrigine	25 mg, 50 mg, 100 mg, 200 mg	Tablets	N28, N30, N42, N50, N56, N60, N98, N100	Antiepileptic drugs	N03AX09
Levetiracetam	250 mg, 500 mg, 750 mg, 1000 mg	Film-coated tablets	N30, N50, N60, N100, N200	Antiepileptic drugs	N03AX14
Lisdexamfetamine dimesylate	20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg	Hard capsules	N10, N28, N30, N50, N90, N100	Centrally Acting Sympathomimetics	N06BA12
Mometasone furoate	1 mg/g	Ointment	15 g, 30 g, 50 g, 100 g	Topical corticosteroid	D07AC13
Mometasone furoate	1 mg/g	Cream	15 g, 30 g, 50 g, 100 g	Topical corticosteroid	D07AC13
Vortioxetine	5 mg, 10 mg, 15 mg, 20 mg	Film coated tablets	N14, N28, N56, N98	Other antidepressants	N06AX26



API development and manufacturing

- Development and optimization of new API production technologies in laboratory scale (10 mL – 10 L reactors)
- Small-scale API manufacturing and process validation under GMP conditions (batch size 1 g – 1 kg)
- Development and validation of highly potent active pharmaceutical ingredients (HPAPIs) (up to band 5) under GMP conditions (batch size 1 g – 1 kg)
- Synthesis of API impurity reference substances, including nitrosamine reference substances
- Organic syntheses of varying complexity and purification of substances (including preparative column chromatography)

List of active pharmaceutical ingredients

Name	Quality application	CAS number	Therapeutic use
Human APIs			
Alfentanil	Ph. Eur. ASMF, CEP*	70879-28-6	Opioid
Apixaban	Ph. Eur. ASMF	503612-47-3	Anticoagulant
Atracurium besilate	Ph. Eur. ASMF, CEP*	64228-81-5	Muscle relaxant
Dexmedetomidine hydrochloride	Ph. Eur. ASMF, USP, JP / Ph. Eur.	145108-58-3	Sedative
Droperidol	Ph. Eur. CEP, Ph. Eur. ASMF, USP ASMF, JP/ USP	548-73-2	Neuroleptic
Fentanyl citrate	Ph. Eur. ASMF, CEP, USP*	990-73-8	Opioid
Fentanyl base	Ph. Eur. ASMF, CEP* , USP*	437-38-7	Opioid
Imatinib mesylate	Ph. Eur. ASMF, CEP*	220127-57-1	Antineoplastic
Levosimendan	Ph. Eur. ASMF	141505-33-1	Cardiac therapy
Midazolam	Ph. Eur. ASMF, USP*	59467-70-8	Sedative
Oxytocin	Ph. Eur. CEP, Ph. Eur. ASMF, USP ASMF	50-56-6	Uterotonic
Rilmenidine dihydrogen phosphate	Ph. Eur. ASMF	85409-38-7	Antihypertensive
Thioguanine	Ph. Eur. ASMF	154-42-7	Cytostatic
Zopiclone	Ph. Eur. CEP, Ph. Eur. ASMF, CA ASMF	43200-80-2	Hypnotic

[*under development](#)

Veterinary APIs			
Atipamezole hydrochloride	Ph. Eur. ASMF, USP VMF Complete Document	104075-48-1	Antidote to α -adrenoceptor induced sedation
Detomidine hydrochloride	Ph. Eur. ASMF, USP VMF Complete Document	90038-01-0	Sedative
Dexmedetomidine hydrochloride	Ph. Eur. ASMF	145108-58-3	Sedative
Medetomidine hydrochloride	Ph. Eur. ASMF, USP VMF Complete Document	86347-15-1	Sedative, analgesic
Oxytocin	Ph. Eur. CEP, Ph. Eur. ASMF, USP VMF Complete Document	50-56-6	Uterotonic
Xylazine	USP VMF Complete Document, USP ASMF	7361-61-7	Sedative, analgesic, muscle relaxant
Xylazine hydrochloride	Ph. Eur. CEP, Ph. Eur. ASMF, USP ASMF	23076-35-9	Sedative, analgesic, muscle relaxant

Available soon			
Apremilast	Ph. Eur. ASMF (available first), JP, USP	608141-41-9	Selective immunosuppressants
Cisatracurium bezilate	Ph. Eur. ASMF (available first), USP	96946-42-8	Muscle relaxant
Esketamine	Ph. Eur. ASMF (available first), USP	33643-46-8	Anesthetic
Mivacurium chloride	Ph. Eur. ASMF	106861-44-3	Muscle relaxant
Norepinephrine / noradrenaline	Ph. Eur. ASMF	51-41-2 108341-18-0 (tartrate H2O)	Cardiac therapy
Remifentanyl	Ph. Eur. ASMF (available first), JP, USP	132539-07-2	Opioid
Vortioxetine	Ph. Eur. ASMF (available first), USP	508233-74-7	Antidepressants




FDF development and manufacturing

Contract development and manufacturing of solid, liquid (sterile, non-sterile), and semi-solid dosage forms. Our experience, modern technologies, and GMP-certified facilities enable us to deliver high-quality and regulatory-compliant pharmaceutical products to partners worldwide. We have dedicated facility for corticosteroid semisolids.

Our Capabilities

- Blending and granulation (wet & dry, fluid bed)
- Tablet compression and coating (pan coating)
- Hard capsule filling (gelatine and HPMC)
- Conventional and flexible processing technologies tailored to client needs



Solid Dosage Forms

- Tablets
- Capsules
- Coated tablets



Semi-Solid Dosage Forms

- Ointments
- Creams
- Gels



Liquid Dosage Forms

- Solutions
- Suspensions
- Syrups



Sterile Liquid Forms

- Small volume parenterals (ampoules)

Grindeks annual production

1.1 billion
tablets

500 million
capsules


12.5 million
tubes

150 million
ampoules

1 million
syrup packages

Analytical services

- Analytical method development
- Analytical method validation, verification and transfer
- Nitrosamine and genotoxic impurity control testing and consulting
- Photostability and forced degradation studies
- Drug–excipient compatibility studies
- Impurity identification studies
- Custom impurity reference standard standardization
- Intrinsic solubility studies



- Equilibrium solubility studies for BCS-based biowaivers
- IVRT method development and analysis
- Rheological behaviour
- Specific surface area determination
- Oxygen determination in the free volume of vials
- Osmolality analysis
- Particulate contamination testing (visible and sub-visible particles)
- Thermal cycle studies (freeze–thaw and cool–thaw cycles)
- Stability studies (accelerated, intermediate, long-term, in-use)

Quality control & quality assurance & batch certification



Quality Control Testing

We offer quality control testing for medicinal products, including imported ones into the European Economic Area from third countries, ensuring that the testing of each medicinal product batch complies with EU standards and regulatory requirements.



Microbiological Testing

We provide microbiological testing for sterile and non-sterile medicinal products, as well as comprehensive support for environmental monitoring programs development.



Stability samples storage and testing

We offer storage and testing of APIs and FDFs for initial and on-going stability studies. We test a wide range of APIs and finished dosage forms, including powders, tablets, capsules, solutions, syrups, ointments, creams, gels, and injectables.



Batch Release

We provide batch certification by experienced Qualified Persons and batch release to the European market.





Our team

Behind every Grindeks product is a team of dedicated professionals working together to improve health and quality of life for millions of people around the world. Today, more than 800 people work at Grindeks, while the Grindeks Group brings together over 1,300 employees.



Grindex



JSC Grindeks

53 Krustpils St, Riga, LV 1057, Latvia

contractservices@grindeks.com

bd@grindeks.com

www.grindeks.com